Kyverna Therapeutics Unveils Strategic Priorities and Anticipated Milestones for 2025 at J.P. Morgan Healthcare Conference

Kyverna Therapeutics, Inc., a leading biotechnology company focusing on autoimmune diseases, revealed its strategic priorities for the year 2025 and anticipated milestones in a recent press release on January 13, 2025. The company’s Chief Executive Officer, Warner Biddle, is set to discuss these developments during the 43rd Annual J.P. Morgan Healthcare Conference.

The press release highlighted key aspects of Kyverna Therapeutics’ plans for 2025, including the announcement of strategic priorities and upcoming milestones. These strategic priorities and anticipated achievements will be further elaborated upon during the presentation at the conference.

The outlined information in the press release, including the strategic priorities and anticipated milestones, is not filed for specific purposes under the Securities Exchange Act of 1934. The details within the press release are not considered as filed material, nor are they incorporated by reference for any future filings under the Securities Act of 1933 or the Securities Exchange Act of 1934 unless explicitly stated.

Kyverna Therapeutics presented two exhibits along with the filing: Exhibit 99.1, a Press Release dated January 13, 2025, and Exhibit 99.2, a Presentation on Pioneering CAR T in Autoimmune Diseases for January 2025. These exhibits shed light on the company’s commitment to advancing innovative treatments in the field of autoimmune diseases.

Looking ahead, Kyverna Therapeutics is aiming to achieve significant milestones in 2025, including completing pivotal Phase 2 enrollment by mid-year, reporting topline pivotal Phase 2 data in the first half of 2026, and targeting a Biologics License Application (BLA) filing in 2026 for Stiff Person Syndrome.

With a focus on delivering the first autoimmune CAR T therapy approved for neuroinflammatory diseases and fast-follow indications in Myasthenia Gravis and Lupus Nephritis, Kyverna Therapeutics is strategically positioned for further growth and expansion.

Combining a strong financial position with a dedicated leadership team and a portfolio of innovative treatments, Kyverna Therapeutics is poised to make significant strides in the autoimmune disease space in 2025 and beyond.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Kyverna Therapeutics’s 8K filing here.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.